

ASTRAZENECA PLC

Interim Financial Statements

30 JUNE 2004

Registered number : 2723534



A13
COMPANIES HOUSE

AM7GRYIQ

0267
14/09/04

ASTRAZENECA PLC

PROFIT AND LOSS ACCOUNT for the period ended 30 June 2004

	Notes	30 June 2004 \$m	31 December 2003 \$m
Turnover			
Operating costs		-	(5)
Operating loss		-	(5)
Income from shares in subsidiary undertakings		-	-
Profit on ordinary activities before interest		-	(5)
Net interest and exchange gains/losses	2	157	354
Profit on ordinary activities before taxation		157	349
Taxation		(47)	(105)
Net profit for the year		110	244
Dividends to Shareholders	3	(494)	(1,350)
Loss retained for the period		(384)	(1,106)

STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES for the period ended 30 June 2004

There are no gains or losses other than those reported above, therefore a statement of recognised gains and losses has not been presented.

ASTRAZENECA PLC


BALANCE SHEET

as at 30 June 2004

	Notes	30 June 2004 \$m	31 December 2003 \$m
Fixed Assets			
Tangible fixed assets		-	-
Fixed asset investments	4	7,744	6,940
		7,744	6,940
Current assets			
External debtors – Other		37	7
Debtors – amounts owed by subsidiaries		24,225	25,339
Cash and short-term investments		-	-
		24,262	25,346
Total assets		32,006	32,286
Creditors due within one year			
Short-term borrowings		(4)	(3)
Other Creditors		(697)	(1,068)
Amounts owed to subsidiaries		(2,684)	(2,049)
		(3,385)	(3,120)
Net current assets		20,877	22,226
Total assets less current liabilities		28,621	29,166
Creditors due after more than one year			
Loans		(1,029)	(295)
		(1,029)	(295)
Provisions for liabilities and charges		-	-
Net Assets		27,592	28,871
Capital and reserves			
Called-up share capital	5	419	423
Share premium account	6	520	449
Capital redemption reserve	6	28	23
Other reserves	6	1,841	1,841
Profit and loss account	6	24,784	26,135
Shareholders' fund – equity interests		27,592	28,871

The financial statements on pages 1 to 5 were approved by the Board of Directors on 22 July 2004 and were signed on its behalf by:

Sir Tom McKillop, Director
Jonathan Symonds, Director



ASTRAZENECA PLC

NOTES RELATING TO THE FINANCIAL STATEMENTS

1 Basis of presentation of financial information

The AstraZeneca PLC accounts are presented in accordance with the accounting policies set out in the 2003 annual accounts.

2 Net interest and exchange gains/losses

	30 June 2004 \$m	31 Dec 2003 \$m
Interest payable and similar charges		
Payable to subsidiary undertakings	(12)	(30)
External interest payable	(4)	-
Net exchange gains/(losses)	19	28
	3	(2)
Interest receivable and similar income		
Receivable from subsidiary undertakings	154	356
	154	356
Net interest and exchange gains/losses	157	354

NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

3 Dividends to Shareholders

	2004 cents per 25c Share	2003 cents per 25c Share	30 June 2004 \$m	31 Dec 2003 \$m
1 st interim	29.5	25.5c	494	436
2 nd interim/final	-	54.0c	-	914
	29.5	79.5c	494	1,350

4 Fixed Asset Investments

	Shares \$m	Loans \$m	Total \$m
Cost or valuation			
At beginning of period	6,645	295	6,940
Additions	70	747	817
Disposals and other movements	-	(13)	(13)
Cost or valuation and net book value at end of period	6,715	1,029	7,744

5 Called-up share capital

	Authorised 2004 \$m	Allotted, called-up and fully paid	
		2004 \$m	2003 \$m
Ordinary Shares (\$0.25 each)	423	423	423
Unissued Ordinary Share (\$0.25 each)	177	-	-
Redeemable Preference Shares (£50,000)	-	-	-
	600	419	423

The movements in share capital during the period can be summarised as follows:

	No of shares (million)	\$m
At beginning of period	1,693	423
Issue of shares	2	1
Repurchase of shares	(21)	(5)
At 30 June 2004	1,674	419

NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

6 Reserves

	Share Premium Account \$m	Capital Redemption Reserve \$m	Other Reserves \$m	Profit and Loss Account \$m	Total 30 June 2004 \$m	Total 31 Dec 2003 \$m
At beginning of period	449	23	1,841	26,135	28,448	30,655
Net gains for the period	-	-	-	110	110	244
Dividends	-	-	-	(494)	(494)	(1,350)
Share Repurchase	-	5	-	(967)	(962)	(1,147)
Share Premiums	71	-	-	-	71	46
At end of period	520	28	1,841	24,784	27,173	28,448
Distributable reserves at end of period	-	-	560	876	1,436	1,592

At 30 June 2004 \$23,908m (31 December 2003 : \$25,032 m) of the profit and loss account reserve was not available for distribution. The majority of this non-distributable amount relates to profit arising on the sale of the Astra AB to a subsidiary in 1999, which becomes distributable as the underlying receivable is settled in cash. During 2004 \$1,124m of the profit was realised by repayment. Subsequent to the period end a further \$985m was repaid on 20 July 2004 resulting in additional distributable reserves not included in the figures above. Included in other reserves is a special reserve of \$157m, arising on the redenomination of share capital in 1999.

7 Reconciliation of Movements in Shareholders' Funds

	30 June 2004 £m	31 Dec 2003 \$m
Net profit for the financial period	110	244
Dividends	(494)	(1,350)
	(384)	(1,106)
Issues of AstraZeneca Ordinary Shares	72	47
Repurchase of AstraZeneca Ordinary Shares	(967)	(1,154)
Net reduction to shareholders' funds	(1,279)	(2,213)
Shareholders' funds at beginning of period	28,871	31,084
Shareholders' funds at end of period	27,592	28,871